FibroTouch技术联合APRI评分评估原发性胆汁性胆管炎患者肝纤维化程度价值分析*

doi:10.3969/j.issn.1672-5069.2026.05.011

摘要/Abstract

摘要： 目的探讨FibroTouch技术联合天冬氨酸氨基转移酶/血小板比值指数(APRI)评分评估原发性胆汁性胆管炎(PBC)患者肝纤维化程度的价值。方法 2021年6月~2025年6月我院诊治的110例PBC患者,均接受肝组织穿刺活检和FibroTouch行肝硬度检测(LSM),常规临床检测,计算APRI。应用受试者工作特征曲线评估诊断效能。结果在110例PBC患者中,组织病理学检查诊断肝纤维化S0期18例,S1期25例,S2期32例,S3期21例和S4期14例,即显著性肝纤维化67例,非显著性肝纤维化43例;随着肝纤维化分期进展,PBC患者LSM值和APRI评分均呈显著升高趋势:S0期LSM值为(5.0±1.1)kPa,APRI评分为(0.3±0.1),S1期分别为(6.8±1.3)kPa和(0.5±0.2),S2期分别为(9.2±2.0)kPa和(0.8±0.3),S3期分别为(12.4±2.7)kPa和(1.4±0.5),S4期分别为(15.8±3.6)kPa和(2.1±0.6),组间比较,差异均有统计学意义(P＜0.05);ROC分析显示,单独应用LSM诊断PBC患者显著性肝纤维化的特异性为94.4%,而应用LSM联合APRI评分预测PBC患者显著性肝纤维化的灵敏度为81.5%,特异度为83.7%。结论采用FibroTouch技术检测LSM联合APRI评分可初步评估PBC患者显著性肝纤维化,为进一步临床处理提供诊断线索。

关键词: 原发性胆汁性胆管炎, 肝硬度检测, 天冬氨酸氨基转移酶/血小板比值指数, 肝纤维化, 诊断

Abstract: Objective The aim of this study was to investigate prediction of significant liver fibrosis (SLF) by FibroTouch detection in combination with aspartate aminotransferase-to-platelet ratio index (APRI) score in patients with primary biliary cholangitis (PBC). Methods A total of 110 patients with PBC were encountered in out hospital between June 2021 and June 2025, all underwent FibroTouch detection for liver stiffness measurement (LSM), and APRI was calculated based clinical materials. Liver biopsies were performed and liver fibrosis was determined by Ludwig staging system. Predicting efficacy was evaluated by receiver operating characteristic (ROC) curves. Results Of the 110 patients with PBC, liver histopathological examination found liver fibrosis S0 in 18 cases, S1 in 25 cases, S2 in 32 cases, S3 in 21 cases and S4 in 14 cases, e.g., SLF in 67 cases and non-SLF (NSLF) in 43 cases; with the progression of liver fibrosis staging, LSM and APRI score increased gradually in PBC patients, e.g., LSM and APRI scores in S0, S1, S2, S3 and S4 were [(5.0±1.1) kPa and (0.3±0.1)], [(6.8±1.3) kPa and (0.5±0.2)], [(9.2±2.0) kPa and (0.8±0.3)], [(12.4±2.7) kPa and (1.4±0.5)] and [(15.8±3.6) kPa and (2.1±0.6)], respectively, with statistically significantly different among different stage groups (P<0.05); ROC analysis showed that the specificity (Sp) was 94.4% by LSM alone in predicting SLF in patients with PBC, while sensitivity was 81.5% and Sp was 83.7% by combination of LSM and APRI score. Conclusion FibroTouch technology in combination with APRI score could preliminarily evaluate SLF in patients with PBC, which might guide clinicians for further interventions.

Key words: Primary biliary cholangitis, Liver stiffness measurement, Aspartate aminotransferase-to-platelet ratio index, Liver fibrosis, Diagnosis

韩敏, 何明玲, 张栋邦, 才新. FibroTouch技术联合APRI评分评估原发性胆汁性胆管炎患者肝纤维化程度价值分析^*[J]. 实用肝脏病杂志, 2026, 29(5): 681-684.

Han Min, He Mingling, Zhang Dongbang, et al. Prediction of significant liver fibrosis by FibroTouch detection in combination with APRI score in patients with primary biliary cholangitis[J]. Journal of Practical Hepatology, 2026, 29(5): 681-684.

参考文献

[1] Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol, 2023,21(8):2076-2087.
[2] Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. HepatolCommun, 2023,7(6):179-181.
[3] Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med, 2024,390(9):795-805.
[4] Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol, 2023,79(2):277-286.
[5] Sukaram T, Maung ST, Chongpison Y, et al. Diagnostic performance of FibroTouch © in assessing hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: An Asian experience. Ann Hepatol, 2025,30(1):1017-1020.
[6] Ashouri Y, Hsu CH, Riall TS, et al. Aspartate aminotransferase-to-platelet ratio index predicts liver failure after resection of colorectal liver metastases. Dig Dis Sci, 2022,67(10):4950-4958.
[7] 任艳,孔明,徐曼曼,等.瞬时弹性成像技术和无创诊断模型诊断原发性胆汁性胆管炎患者肝纤维化效能研究.实用肝脏病杂志, 2024, 27(5):725-728.
[8] 张奉春,王立,帅宗文,等.原发性胆汁性胆管炎诊疗规范(2021年).中华内科杂志, 2021, 60(8):709-715.
[9] Liedtke C, Nevzorova YA, Luedde T, et al. Liver fibrosis-from mechanisms of injury to modulation of disease. Front Med (Lausanne), 2022,11(8):8144-8149.
[10] Trivedi PJ, Hirschfield GM, Adams DH, et al. Immunopathogenesis of primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis: themes and concepts. Gastroenterology,2024,166(6):995-1019.
[11] 任浩,熊清芳.多种无创检测指标预测自身免疫性肝病患者肝硬化效能比较.实用肝脏病杂志, 2024, 27(4):535-538.
[12] Liao Y, Liu L, Yang J, et al. Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch. Sci Rep, 2023,13(1):1481-1489.
[13] 王燕燕,周桐桐,卞兆连.原发性胆汁性胆管炎和原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征患者临床与肝组织病理学特点分析.实用肝脏病杂志, 2024, 27(5):721-724.
[14] Zhang X, Xin Y, Yang Y, et al. Aspartate aminotransferase-to-platelet ratio index for predicting late recurrence of hepatocellular carcinoma after radiofrequency ablation. Int J Hyperthermia,2022,39(1):437-445.
[15] Wang M, Li Y, Cao Y, et al. Aspartate aminotransferase-to-platelet ratio index as a novel predictor of early mortality in heat stroke patients: a multi-centre retrospective study. Ann Med, 2025,57(1):2478-2480.
[16] Kwon H, Kim MG, Oh S, et al. Application of quantitative ultrasonography and artificial intelligence for assessing severity of fatty liver: a pilot study. Diagnostics (Basel),2024,14(12):1237-1240.
[17] Ye X, He L, Deng C, et al.Noninvasive elastography-based assessment of liver fibrosis in primary biliary cholangitis. Ann Hepatol, 2025,31(1):1021-1024.
[18] Jang SY, Yoon KT, Cho YY, et al. Aspartate aminotransferase-to-platelet ratio index outperforms Fibrosis-4 in 2843 Korean patients with metabolic dysfunction-associated steatotic liver disease. Hepatol Res, 2025,55(4):479-491.
[19] Bhayani PD, Parameswaran SA, Palaniswamy KR, et al. Is aspartate aminotransferase to platelet ratio index a better noninvasive score for predicting advanced fibrosis in nonalcoholic fatty liver disease patients? Euroasian J Hepatogastroenterol, 2024,14(1):35-39.
[20] Yin D, Wu J, Wang Y, et al. Aspartate aminotransferase-to-platelet ratio index as predictors of recompensation in decompensated cirrhosis. J Coll Physicians Surg Pak, 2025,35(2):168-173.

FibroTouch技术联合APRI评分评估原发性胆汁性胆管炎患者肝纤维化程度价值分析^*

Prediction of significant liver fibrosis by FibroTouch detection in combination with APRI score in patients with primary biliary cholangitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马庆亮, 刘鸣昊. 肝细胞外泌体在肝纤维化发生发展过程中的作用研究进展^*[J]. 实用肝脏病杂志, 2026, 29(5): 641-644.
[2]	赵先群, 闫斌斌, 李德洋, 田春阳, 张向东. 原发性胆汁性胆管炎患者临床特征、自身抗体特点和预后分析^*[J]. 实用肝脏病杂志, 2026, 29(5): 685-688.
[3]	王海玉, 张志博, 王倩, 刘翠翠, 王燕妮. 超声衰减系数成像评估儿童和青少年肝豆状核变性肝损害应用研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 697-700.
[4]	文婷, 贾雨阳, 冯流平. 肝脏磁共振DWI参数预测肝硬化并发高风险食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 709-712.
[5]	赵宇皓, 张和钊, 张瑞, 史志勇, 樊永强, 刘晓东, 徐钧. 基于血清IL-34、ADR和MELD评分构建早期移植物功能障碍预警模型:一项肝移植预后评估研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 745-748.
[6]	王文轩, 李杰, 王馨蕊, 曹澍, 吴迪. CT与MRI增强扫描诊断胆管癌临床分期价值分析^*[J]. 实用肝脏病杂志, 2026, 29(5): 781-784.
[7]	马广骏, 祝青松, 孟祥华. CT多模式重建技术诊断肝门部胆管癌临床分期价值研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 785-788.
[8]	阮方, 孔文君. 慢性肝病眼部表现介绍^*[J]. 实用肝脏病杂志, 2026, 29(5): 796-799.
[9]	吴芃萱, 刘晖, 郑素军. 伴有脂肪肝的遗传代谢性肝病诊断策略^*[J]. 实用肝脏病杂志, 2026, 29(4): 481-484.
[10]	刘莹, 马小宏, 孙长江, 陈爱莲. 超声脂肪分数联合RC/HDL-C比值评估MAFLD患者肝脂肪变性程度价值研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 513-516.
[11]	郭鸿雁, 王蕊, 孙倩. 2型糖尿病合并非酒精性脂肪性肝病患者血糖控制水平与氧化应激和早期肝纤维化的关系探讨[J]. 实用肝脏病杂志, 2026, 29(4): 521-524.
[12]	彭艳侠, 翟盟. 超声衰减成像联合BMI诊断肥胖儿童代谢功能障碍相关性脂肪性肝病价值研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 525-528.
[13]	朱晨晨, 庄晓晨, 杨凌菲, 王颖鑫. 基于QUS技术判定非酒精性脂肪性肝病患者肝脂肪变性分级价值研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 529-532.
[14]	冯岩, 张鑫赫, 李异玲. 合并中-重度界面炎显著增加原发性胆汁性胆管炎患者治疗不完全应答风险:一项回顾性队列研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 533-536.
[15]	邱佳睿, 张馨, 焦娇. 熊去氧胆酸联合肝爽颗粒治疗原发性胆汁性胆管炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 537-540.